The SLP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SLP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The SLP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View SLP Detailed Price Forecast - CNN Money||View SLP Detailed Summary - Google Finance|
|View SLP Detailed Summary - Yahoo! Finance||View SLP Stock Research & Analysis - Zacks.com|
|View SLP Trends & Analysis - Trade-Ideas||View SLP Major Holders - Barrons|
|View SLP Call Transcripts - NASDAQ||View SLP Breaking News & Analysis - Seeking Alpha|
|View SLP Annual Report - CompanySpotlight.com||View SLP OTC Short Report - OTCShortReport.com|
|View SLP Fundamentals - TradeKing||View SLP SEC Filings - Bar Chart|
|View Historical Prices for SLP - The WSJ||View Performance/Total Return for SLP - Morningstar|
|View the Analyst Estimates for SLP - MarketWatch||View the Earnings History for SLP - CNBC|
|View the SLP Earnings - StockMarketWatch||View SLP Buy or Sell Recommendations - MacroAxis|
|View the SLP Bullish Patterns - American Bulls||View SLP Short Pain Metrics - ShortPainBot.com|
|View SLP Stock Mentions - StockTwits||View SLP Stock Mentions - PennyStockTweets|
|View SLP Stock Mentions - Twitter||View SLP Investment Forum News - Investor Hub|
|View SLP Stock Mentions - Yahoo! Message Board||View SLP Stock Mentions - Seeking Alpha|
|View Insider Transactions for SLP - SECform4.com||View Insider Transactions for SLP - Insider Cow|
|View SLP Major Holdings Summary - CNBC||View Insider Disclosure for SLP - OTC Markets|
|View Insider Transactions for SLP - Yahoo! Finance||View Institutional Holdings for SLP - NASDAQ|
|View SLP Stock Insight & Charts - FinViz.com||View SLP Investment Charts - StockCharts.com|
|View SLP Stock Overview & Charts - BarChart||View SLP User Generated Charts - Trading View|
Ex-Dividend Schedule: Simulations Plus Has a Dividend Yield of 1.32%; Will Trade Ex-Dividend on July 25, 2018
Posted on Tuesday July 24, 2018
LONDON, UK / ACCESSWIRE / July 24, 2018 / Active-Investors has a free review on Simulations Plus, Inc. (NASDAQ: SLP) following the Company's announcement that it will begin trading ex-dividend on July 25, 2018. To capture the dividend payout, investors must purchase the stock a day prior to the ex-dividend date that is by latest at the end of the trading session on July 24, 2018. Active-Investors has initiated due-diligence on this dividend stock.
Simulations Plus Subsidiary DILIsym Awarded Grant for up to $1.7 Million For Model Development
Posted on Monday July 23, 2018
DILIsym Services, Inc., a Simulations Plus company (SLP) developing in silico modeling software, resources, and information for assisting the pharmaceutical industry to more efficiently develop safe and effective drug therapies, today announced it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant by the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK). The grant, coauthored by Dr. Brett Howell (Principal Investigator) and Dr. Bud Nelson, is entitled “Software for predicting a drug’s potential to cause acute kidney injury.” The total award for this Fast Track SBIR grant is up to $1.7 million over the next 18-24 months.
Simulations Plus Enters Funded Research Collaboration with Large European Consortium
Posted on Wednesday July 18, 2018
Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a one-year funded research collaboration with a large European consortium to further develop and validate the mechanistic Transdermal Compartmental Absorption and Transit (TCAT™) model in GastroPlus™. Dr. Viera Lukacova, director of simulation sciences, said: “We are very pleased to have the opportunity to work with the diverse membership of this large European consortium to enhance the GastroPlus TCAT model in support of alternative approaches to animal testing. The model is already being utilized heavily within pharmaceutical companies to support transdermal product development activities.
Edited Transcript of SLP earnings conference call or presentation 10-Jul-18 8:15pm GMT
Posted on Tuesday July 17, 2018
Q3 2018 Simulations Plus Inc Earnings Call